Gallic Acid Bismuth Basic Salt
Gallic Acid Bismuth Basic Salt Uses, Dosage, Side Effects, Food Interaction and all others data.
Gallic Acid Bismuth Basic Salt is a yellow colored substance that presents as an odorless powder that undergoes discoloration when exposed to sunlight. It is a heavy metal salt of gallic acid that is highly insoluble and poorly absorbed. Possessing protective effects on the gastric mucosa, strong astringent effects, and not as yet elucidated antimicrobial and hemostatic actions, bismuth subgallate is most commonly available as an over-the-counter internal deodorant where it is often employed as the primary active ingredient.
Gallic Acid Bismuth Basic Salt is a heavy metal salt that is relatively insoluble and poorly absorbed . As a result, systemic absorption is not necessary or possibly even desired when the agent is administered orally or onto specific otorhinolaryngology and/or dermatologic wound sites where it can execute its pharmacologic action directly within the gastrointestinal lumen to deodorize flatulence and stools or potentially elicit a hemostatic effect on wounds .
Additionally, like other bismuth agents, one of the most common side effects associated with bismuth subgallate is its propensity to cause a black discoloration of the tongue and stools when the agent combines with trace amounts of sulfur in the saliva and/or gastrointestinal tract . This discoloration is temporary and harmless, gradually dissipating over a number of days and eventually disappearing after the discontinuation of the bismuth agent .
| Trade Name | Gallic Acid Bismuth Basic Salt |
| Generic | Bismuth subgallate |
| Bismuth subgallate Other Names | basisches Wismutgallat, Bismuth subgallate, Bismuto subgalato, gallic acid bismuth basic salt, Wismutgallathydroxid |
| Type | |
| Formula | C7H5BiO6 |
| Weight | Average: 394.091 Monoisotopic: 393.98901 |
| Protein binding | In general, any systemic absorption of bismuth subgallate is expected to be low but any bismuth that is absorbed is also expected to bind to plasma proteins and be distributed throughout all tissues , with the highest concentration found in the kidney and lower levels in the lung, spleen, liver, brain, bone, and muscle . The bismuth component itself is generally known to demonstrate a high percentage binding to plasma proteins of >90% . |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Gallic Acid Bismuth Basic Salt is a medication used to deodorize flatulence and stools as well as hemostasis in soft tissue surgery.
The most common medical purpose for which bismuth subgallate is currently and formally indicated for is the use as a non-prescription internal deodorant product for the purpose of deodorizing flatulence and stools .
Additionally, there are also various non-prescription (over the counter) bismuth subgallate based wound healing products as well as ongoing studies into whether or not the substance can be utilized as a legitimate hemostatic agent - usually for soft tissue surgery in otorhinolaryngology and/or dermatologic settings .
Moreover, in the past bismuth subgallate may have seen some use as a treatment for Helicobacter pylori infection . In contrast, contemporary first-line therapies generally involve proton pump inhibitor and antibiotic combination therapies that generally achieve high rates of pathogen eradication, ease of administration, and patient compliance.
Gallic Acid Bismuth Basic Salt is also used to associated treatment for these conditions: Anal Fissures, Hemorrhoids, Malodorous flatulence, Pruritus Ani, Malodorous stool
How Gallic Acid Bismuth Basic Salt works
Bismuth salts exert their action largely in the upper gastrointestinal tract by way of local activity from luminal bismuth in the stomach and duodenum .
In terms of bismuth subgallate's ability to deodorize flatulence and stools as an internal deodorant - although not fully elucidated - it is believed that when the substance is administered orally, its relative insolubility and poor absorption allows it to remain within the gastrointestinal lumen and inhibit colonic bacteria from acting on fermentable food residues in the GI tract .
Moreover, when bismuth subgallate is taken orally, various salts like bismuth citrate, bismuth oxychloride, and others are formed . These salts are then taken up into surrounding gastric mucus as well as bound to protein within the base of any ulcers that may be present after coming into contact with gastric juice . Additionally, bismuth compounds like bismuth subgallate are also believed to have the capacity to trigger the secretion of prostaglandins, epithelial growth factor (EGF), and mucosal bicarbonate as a means to inhibit the action of pepsin in gastric juice . These actions subsequently protect gastric mucous from peptic luminal degradation as well as enhance the properties of mucous to assist in the healing of both duodenal and gastric ulcers . In this way, bismuth subgallate works to absorb extra water and/or toxins in the large intestine, allowing it to form a protective coat on the intestinal mucosa and over ulcers that may or may not be associated with infections like those of Helicobacter pylori .
Furthermore, studies have shown that bismuth compounds like bismuth subgallate are capable of demonstrating antimicrobial effects against various gastrointestinal tract pathogens like E. coli, Salmonella, Shigella, Vibrio cholera, Campylobacter jejuni, H. pylori, and some enteric viruses like Rotaviruses . Although the exact mechanism(s) of action by which bismuth compounds are able to elicit such antimicrobial effects remains unclear , a number of experimental observations suggest that bismuth has been able to complex with the bacterial wall and periplasmic membrane; inhibit bacterial enzymes like urease, catalase, and lipase; inhibit bacterial protein and ATP synthesis; and also inhibit or decrease the adherence of bacteria like H. pylori to epithelial cells . In essence, ultrastructural studies have shown evidence of the binding of bismuth complexes to the bacterial wall and periplasmic space between the inner and outer bacterial membrane of H.pylori with subsequent ballooning and disintegration of the pathogen . To various extents, these antimicrobial actions may also illustrate how bismuth subgallate is capable of neutralizing colonic bacteria from acting on fermentable foods as well.
Numerous studies have and continue to study the possible hemostatic action that bismuth subgallate may have. As the bismuth salt of gallic acid, bismuth subgallate's chemical structure shares similarities to ellagic acid, another gallic acid derivative . Ellagic acid itself is a clot-promoting agent that initiates thrombin formation by way of the intrinsic pathway via an action on Hageman factor (clotting factor XII) . It is believed that bismuth subgallate's ability to activate factor XII is associated with the chemical's negatively charged moieties - whose contact with factor XII would theoretically initiate the intrinsic pathway to blood clotting .
Other studies have also suggested that bismuth subgallate is capable of inducing macrophages to secrete growth factors to facilitate wound healing, decreasing lesion area, enhancing granulation tissue formation and re-epithelialization, the initiation of the proliferation of collagen via the activation of fibroblasts, the accelerated re-establishment of blood vessels, and also the restriction of nitric oxide formation .
Given such studies regarding bismuth subgallate's potential hemostatic abilities, there has been and continues to be interest in indicating the agent for use in otolaryngology as in tonsillectomies or adenotonsillectomies to achieve reduced bleeding and surgery times; topical treatment in various open wound surgeries to facilitate faster and earlier clotting between tissues; ileostomy; dental surgeries; epistaxis management; among others . Nevertheless, study results are conflicting; where there may be experimental results suggesting some improvements in reduced operation time and operative blood loss when bismuth subgallate is used as a hemostatic agent in tonsillectomies there are also study results that observed bismuth subgallate having a negative influence on the healing processes of wounds inflicted in animal models, in which the use of the agent actually delayed the rate of new vessel formation and optimal wound healing .
Finally, bismuth subgallate also demonstrates a strong astringent ability - an action that can facilitate both its deodorant and hemostatic effects and assists in its indication as an active ingredient in a number of non-prescription products for hemorrhoid suppositories or topical applications, diarrhea, etc .
Toxicity
Depending on the level of severity of a patient's renal impairment, administration of bismuth compounds may not be appropriate as the reduced renal clearance can lead to undesirably elevated blood levels of bismuth . Similarly, because of the biliary excretion of bismuth, severe liver disease may theoretically result in accumulation of bismuth as well .
Bismuth toxicity seemingly develops only from excessive dosage (perhaps from ingestion of bismuth over a prolonged time or intramuscular injections) and is characterized by nephrotoxicity, osteoarthropathy, encephalopathy, hepatotoxicity, stomatitis, and gingivitis . However, the insoluble inorganic bismuth compounds are reported to be mainly associated with reversible encephalopathy . In fact a number of studies have discussed how patients may experience a syndrome of subacute, progressive encephalopathy involving potential aphasia, myoclonous, and/or gait instability after taking bismuth subgallate in large quantities well over the usual recommended dosages . This kind of encephalopathy is usually reversible with the discontinuation of the bismuth subgallate usage however .
Food Interaction
No interactions found.Volume of Distribution
In general, oral administration is one of the most common routes of administration for non-prescription bismuth subgallate products and gastrointestinal and systemic absorption is usually very low.
Elimination Route
Gallic Acid Bismuth Basic Salt is only slightly, if at all, absorbed after oral ingestion . The general human oral bioavailability of bismuth subgallate has been reported as low as 0.04% . Any absorption that does occur is likely to happen from the upper small intestine .
The gastrointestinal absorption of bismuth from bismuth compounds demonstrates a large interindividual variation . Factors affecting the absorption involve the formulation of the bismuth subgallate compound as well as the dietary factors of the individuals themselves . Nevertheless, absorption can be enhanced with the concomitant intake of citrate and sulfhydryl-group-containing compounds . Conversely, the simultaneous administration of antacids or a diet that is high in thiol content can lower absorption of bismuth subgallate .
Half Life
The bismuth component of bismuth subgallate is known to have a terminal half-life of 21-72 days .
Clearance
On average, the blood clearance of the bismuth component of a bismuth salt like bismuth subgallate is within the range of 50 to 95 ml/min .
Elimination Route
Ingested bismuth is primarily eliminated unabsorbed by way of the faeces . Any absorbed bismuth is eliminated from the body by both the urinary and faecal (including bile) routes . Excretion of absorbed bismuth in the urine is rapid, with most of the metal excreted within 24 hours . About 10% of the absorbed bismuth is detected in faeces, presumably owing to biliary secretion .
Innovators Monograph
You find simplified version here Gallic Acid Bismuth Basic Salt
